[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Khan et al., 1991 - Google Patents

Bee venom anti-idiotypic antibody is associated with protection in beekeepers and bee sting-sensitive patients receiving immunotherapy against allergic reactions

Khan et al., 1991

View PDF
Document ID
9351268289849668983
Author
Khan R
Szewczuk M
Day J
Publication year
Publication venue
Journal of allergy and clinical immunology

External Links

Snippet

Bee venom (BV) anti-idiotypic (anti-Id) antibodies (Abs) were studied in nonreactive beekeepers, patients receiving BV immunotherapy (IT), and in patients with bee-sting hypersensitivity. Detection of serum anti-BV was determined either by the Phadebas RAST …
Continue reading at www.jacionline.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
Golden et al. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy
Niederberger et al. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations
National Research Council et al. Biologic markers in immunotoxicology
Platts-Mills et al. Occupational asthma and rhinitis related to laboratory rats: serum IgG and IgE antibodies to the rat urinary allergen
Schumacher et al. Allergy to murine antigens in a biological research insitute
Bircher et al. IgE to food allergens are highly prevalent in patients allergic to pollens, with and without symptoms of food allergy
Djurup et al. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens
Rossi et al. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy
Marsh et al. Immune responsiveness to Ambrosia artemishfolia (short ragweed) pollen allergen Amb a VI (Ra6) is associated with HLA-DR5 in allergic humans
Lebecque et al. Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1
Peng et al. Quantitative IgE-and IgG-subclass responses during and after long-term ragweed immunotherapy
Purohit et al. Poor association between allergen‐specific serum immunoglobulin E levels, skin sensitivity and basophil degranulation: a study with recombinant birch pollen allergen Bet v 1 and an immunoglobulin E detection system measuring immunoglobulin E capable of binding to FcɛRI
Jarvis et al. Cat and dust mite allergen levels, specific IgG and IgG4, and respiratory symptoms in adults
Løwenstein et al. Identification of allergens in extract of horse hair and dandruff by means of crossed radioimmunoelectrophoresis
Khan et al. Bee venom anti-idiotypic antibody is associated with protection in beekeepers and bee sting-sensitive patients receiving immunotherapy against allergic reactions
Taketomi et al. Differential IgE reactivity to Der p 1 and Der p 2 allergens of
Cunnick et al. Alterations in specific antibody production due to rank and social instability
Chapman Purification of allergens
Marsh et al. Basal serum IgE levels and HLA antigen frequencies in allergic subjects: I. Studies with ragweed allergen Ra3
Khaitov et al. Recombinant PreS‐fusion protein vaccine for birch pollen and apple allergy
Arbesman et al. Allergenic potency of bee antigens measured by RAST inhibition
Castracane et al. Detection of human auto-anti-idiotypic antibodies (Ab2) II. Generation of Ab2 in atopic patients undergoing allergen immunotherapy
Michils et al. Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression
Riario-Sforza et al. Sensitization to cockroach in Italy: a multicentric study
Reid et al. Mountain cedar pollinosis: can it occur in non-atopics?